Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Carcinoma
|
103 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.020 | 1.000 | 2 | 2014 | 2015 | ||||||
Nodule
|
19 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.020 | 0.500 | 2 | 2015 | 2018 | ||||||
Non-small cell lung cancer recurrent
|
4 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.020 | 1.000 | 2 | 2015 | 2017 | ||||||
Non-squamous non-small cell lung cancer
|
4 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.020 | 1.000 | 2 | 2016 | 2018 | ||||||
Secondary malignant neoplasm of bone
|
18 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.020 | 1.000 | 2 | 2015 | 2017 | ||||||
Secondary malignant neoplasm of lung
|
20 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.020 | 1.000 | 2 | 2014 | 2016 | ||||||
Tumor Cell Invasion
|
169 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.020 | 1.000 | 2 | 2015 | 2018 | ||||||
Adenocarcinoma of lung stage IIIB
|
3 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||||
Adenocarcinoma of small intestine
|
5 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2013 | 2013 | ||||||
Adenocarcinoma, metastatic
|
3 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2005 | 2005 | ||||||
Adult Penile Carcinoma
|
3 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2013 | 2013 | ||||||
Advanced lung cancer
|
9 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2009 | 2009 | ||||||
Androgen-Insensitivity Syndrome
|
176 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||||
Bronchioloalveolar Adenocarcinoma
|
5 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2006 | 2006 | ||||||
Carcinoma breast stage IV
|
14 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||||
Carcinoma, Large Cell
|
6 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||||
Carcinoma, Ovarian Epithelial
|
327 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2007 | 2007 | ||||||
CNS metastases
|
14 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||
Diarrhea
|
63 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||||
Exanthema
|
14 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||||
HER2 gene amplification
|
14 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||
Hyperplastic Polyp
|
22 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2020 | 2020 | ||||||
Laryngeal Squamous Cell Carcinoma
|
30 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||||
Li-Fraumeni Syndrome
|
206 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||||
Lymphatic Metastasis
|
10 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2015 | 2015 |